Curaleaf Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Curaleaf Holdings wird ein Gewinn- und Umsatzwachstum von 32.6% bzw. 13.5% pro Jahr prognostiziert, während der Gewinn pro Aktie um 40.2% pro Jahr wachsen soll.

Wichtige Informationen

32.6%

Wachstumsrate der Gewinne

40.2%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	53.4%
Wachstumsrate der Einnahmen	13.5%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	18 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Investors Give Curaleaf Holdings, Inc. (TSE:CURA) Shares A 27% Hiding

Nov 09

Curaleaf Holdings, Inc. (TSE:CURA) Shares Slammed 25% But Getting In Cheap Might Be Difficult Regardless

Aug 13

These 4 Measures Indicate That Curaleaf Holdings (TSE:CURA) Is Using Debt Extensively

Jul 19

Some Confidence Is Lacking In Curaleaf Holdings, Inc. (TSE:CURA) As Shares Slide 27%

Jun 14

Subdued Growth No Barrier To Curaleaf Holdings, Inc. (TSE:CURA) With Shares Advancing 25%

Jan 19

Gewinn- und Umsatzwachstumsprognosen

TSX:CURA - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	1,859	N/A	N/A	N/A	2
12/31/2025	1,479	-131	113	198	9
12/31/2024	1,351	-171	73	142	9
9/30/2024	1,357	-206	39	129	N/A
6/30/2024	1,360	-221	54	134	N/A
3/31/2024	1,353	-237	46	111	N/A
12/31/2023	1,347	-230	5	75	N/A
9/30/2023	1,342	-346	-7	74	N/A
6/30/2023	1,334	-318	-35	71	N/A
3/31/2023	1,312	-268	-127	9	N/A
12/31/2022	1,275	-258	-88	46	N/A
9/30/2022	1,244	-157	-137	22	N/A
6/30/2022	1,234	-202	-150	11	N/A
3/31/2022	1,232	-223	-170	-7	N/A
12/31/2021	1,196	-206	-230	-58	N/A
9/30/2021	1,118	-164	-201	-27	N/A
6/30/2021	984	-90	-237	-89	N/A
3/31/2021	790	-57	-127	8	N/A
12/31/2020	627	-57	-114	12	N/A
9/30/2020	472	-52	-110	-25	N/A
6/30/2020	351	-50	-86	5	N/A
3/31/2020	282	-72	-110	-23	N/A
12/31/2019	221	-67	-120	-38	N/A
9/30/2019	178	-57	-124	-37	N/A
6/30/2019	137	-84	-121	-50	N/A
3/31/2019	103	-64	-101	-45	N/A
12/31/2018	77	-56	-78	-33	N/A
9/30/2018	51	-40	-49	-20	N/A
6/30/2018	36	-6	N/A	-10	N/A
3/31/2018	25	-3	N/A	-10	N/A
12/31/2017	19	-3	N/A	-8	N/A
12/31/2016	4	0	N/A	-2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CURA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CURA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CURA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CURADie Einnahmen des Unternehmens (13.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Canadian (7.1% pro Jahr).

Hohe Wachstumseinnahmen: CURADie Einnahmen des Unternehmens (13.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CURA in 3 Jahren voraussichtlich hoch sein wird

Curaleaf Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 10%

Consensus EPS estimates fall by 17%

Consensus EPS estimates fall by 36%

Consensus EPS estimates fall by 66%

Forecast breakeven date moved forward to 2023

Forecast to breakeven in 2025

Recent updates

New minor risk - Share price stability

Investors Give Curaleaf Holdings, Inc. (TSE:CURA) Shares A 27% Hiding

Consensus EPS estimates fall by 10%

Curaleaf Holdings, Inc. (TSX:CURA) acquired Half Moon Nursery, Inc. and The assets of Dark Heart Nursery from Grace & Co., Inc. for approximately $2 million.

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Curaleaf Holdings, Inc. to Report Q3, 2024 Results on Nov 06, 2024

New minor risk - Profitability

Curaleaf Holdings, Inc. (TSE:CURA) Shares Slammed 25% But Getting In Cheap Might Be Difficult Regardless

New minor risk - Profitability

Second quarter 2024 earnings: EPS misses analyst expectations

These 4 Measures Indicate That Curaleaf Holdings (TSE:CURA) Is Using Debt Extensively

Curaleaf Holdings, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Some Confidence Is Lacking In Curaleaf Holdings, Inc. (TSE:CURA) As Shares Slide 27%

Executive Vice-Chairman recently sold CA$706k worth of stock

Consensus EPS estimates fall by 17%

Curaleaf Holdings, Inc. (TSX:CURA) completed the acquisition of Northern Green Canada Inc. (NGC).

Curaleaf Holdings, Inc., Annual General Meeting, Jun 14, 2024

Curaleaf Holdings, Inc. to Report Q1, 2024 Results on May 09, 2024

Curaleaf Holdings, Inc. (TSX:CURA) signed a deal to acquire Northern Green Canada Inc. (NGC).

Subdued Growth No Barrier To Curaleaf Holdings, Inc. (TSE:CURA) With Shares Advancing 25%

Curaleaf Expands Zero Proof™ Brand Portfolio with Launch of Stir Fast-Acting THC Beverage Mix

Does Curaleaf Holdings (CSE:CURA) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 36%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Curaleaf Holdings, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Executive Vice-Chairman recently sold CA$860k worth of stock

Is Curaleaf Holdings (CSE:CURA) Using Too Much Debt?

Curaleaf Expands Brand Portfolio with Launch of Zero Proof ™ Cannabis-Infused Drinkables

Curaleaf Holdings, Inc., Annual General Meeting, Oct 04, 2023

Curaleaf Holdings, Inc.'s Select™ Brand Expands Product Offerings With Launch of Select Liquid Diamonds

Second quarter 2023 earnings: EPS misses analyst expectations

Curaleaf Holdings, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Curaleaf Holdings, Inc. Unveils Strategic National Rebrand of Select

New minor risk - Shareholder dilution

Curaleaf Holdings (CSE:CURA) Has Debt But No Earnings; Should You Worry?

Consensus EPS estimates fall by 66%

Forecast breakeven date moved forward to 2023

Full year 2022 earnings: Revenues in line with analyst expectations

Less than half of directors are independent

Curaleaf Holdings, Inc. Announces Closure of Operations in California, Colorado and Oregon

Forecast to breakeven in 2025

Less than half of directors are independent

Curaleaf Holdings, Inc. Announces Expansion of BlueKudu Infused Chocolate Flavors Available on Florida Retail Menus

Curaleaf Holdings, Inc. Announces the Launch of Adult-Use Sales At Its Bordentown, New Jersey Location

Curaleaf Holdings Relocates Deerfield, IL Dispensary and Opens Doors to Adult-Use Customers

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) completed the acquisition of Tryke Companies, LLC for approximately $180 million.

Executive Vice-Chairman recently sold CA$160k worth of stock

We Think Curaleaf Holdings (CSE:CURA) Is Taking Some Risk With Its Debt

No longer forecast to breakeven

Consensus EPS estimates fall by 42%

No longer forecast to breakeven

Curaleaf Holdings, Inc., Annual General Meeting, Sep 08, 2022

Curaleaf Holdings, Inc. Announces Management Appointments

Curaleaf Holdings, Inc. Launches Plant Precision, New Product Line Targeting Specific Health and Wellness Categories

Consensus forecasts updated

Curaleaf Holdings, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Curaleaf Expands New Jersey Adult-Use Sales to Edgewater Park Dispensary

Curaleaf Expands New Jersey Adult-Use Sales to Edgewater Park Dispensary

Here's Why Curaleaf Holdings (CSE:CURA) Has A Meaningful Debt Burden

First quarter 2022 earnings: EPS exceeds analyst expectations

Curaleaf Holdings, Inc. Reports Impairment Loss for the Quarter Ended March 21, 2022

Curaleaf Holdings, Inc. Announces Executive Changes

Consensus forecasts updated

Forecast breakeven date pushed back to 2023

Curaleaf Holdings, Inc Expands Product Offerings With Launch of BlueKudu Chocolates in Florida

Curaleaf Holdings, Inc., Annual General Meeting, Jun 23, 2022

Curaleaf Holdings, Inc. Announces its Select Brand Launches Limited-Edition Cliq Elite Live Strain in California

Curaleaf Holdings, Inc. to Report Q1, 2022 Results on May 09, 2022